Chaga Mushroom (Inonotus obliquus): A Comprehensive Reference
1. Identity and Botanical Classification
Scientific Name and Taxonomy
The fungus is formally named Inonotus obliquus (Fr.) Pilát, with a synonym Fuscoporia obliqua (Fr.) Aoshima, and belongs to the family Hymenochaetaceae. It grows on the trunks of deciduous trees, especially Betula (birch) species, and is a parasitic white rot fungus. It is a sterile, tree-destroying fungus that parasitizes the trunks of living birches and belongs to the family Hymenochaetaceae, thriving in humid parts of Europe, Asia, and North America.
Morphology and Physical Structure
Although it is typically referred to as a mushroom, chaga is actually a sclerotia — a hardened mass of fungal mycelium. As a parasitic fungus, chaga primarily grows on birch trees in cold climates, like those in Canada, Siberia, Scandinavia, and some parts of the United States. Its sclerotium, the asexual stage, appears as a gall-like structure with a very irregular shape (0.5–1.5 m long and 10–15 cm thick) and a cracked and deeply fissured surface on the damaged bark of living trees. Chaga appears as a charred, charcoal-like mass with a woody, orange interior.
Common Names and Etymology
The term "chaga" most probably derives from Russian. Chaga is also known as birch conk (a woody growth), clinker polypore, cinder conk, and black mass, and is usually found on the boles of birch trees, though occasionally on other trees including alder, ash, beech, chestnut, hornbeam, plane-tree, poplar, maple, rowan, oak, walnut, and willow. The word "chaga" is derived from the old Russian word for "mushroom," and the word stems from Komi-Permyak, the language of the indigenous people living near the Ural Mountains.
Geographic Distribution
Chaga is commonly found in cooler climates, extending from the meridian zone in the mountains to the Northern Hemisphere in subarctic regions. This mushroom is well known on three continents, including the cold climate regions of North America at latitudes of 45°N–50°N (Canada and the United States of America), Asia (Russia, Kazakhstan, Siberia, South Korea, and Japan), and Central and Northern Europe. Its growth is restricted to cold habitats of 45–50°N, including Finland, Germany, and Poland.
Common Forms and Preparations
Although edible, chaga mushroom is not commonly consumed in its raw form due to its bitter nature. Instead, tea made from the whole mushroom is more popular. Chaga extracts are also marketed as supplements in the form of capsules, tablets, and teas for their antioxidant and immunostimulatory effects. Chaga is most commonly sold as a dried extract in powder or capsule form but is also available as a liquid tincture.
Extraction method significantly affects the chemical profile of finished preparations. Tinctures are liquid extracts, often made using a dual extraction method (water and alcohol). This process aims to capture a broader spectrum of chaga's beneficial compounds, including both water-soluble (like polysaccharides) and alcohol-soluble (like triterpenoids) constituents. Tinctures are generally more potent than powders or teas. Chaga has chitin-rich cell walls that are difficult to break down without extraction; traditional preparation methods use hot water extraction to release water-soluble constituents.
2. Traditional and Historical Use
Earliest Documented Use
According to historical records, the Khanty people of Western Siberia were the first to use chaga medicinally, perhaps in the 12th century. The native Siberians would grind it up and add it to their everyday beverages, soups, and stews. The Khanty people of Western Siberia used chaga "for general well-being, internal cleaning and curing and preventing disease in general, but in particular for liver problems, heart problems, tuberculosis and to get rid of parasitic worms."
The indigenous Ainu people of the Hokkaido, Sakhalin, and Kuri Island areas would perform religious ceremonies while smoking pipes of chaga, as well as drink it as a tea to treat inflammatory conditions.
Russia and Northern Europe
During the 16th to 17th century, the medicinal properties of chaga became more formally recognized in medical texts. Chaga appears many times in the traditional folk medicine books of Russia and Northern Europe, which note the use of chaga to treat cancer, gastritis, ulcers, and tuberculosis. It was recorded that the Grand Duke of Kievan Rus, Tsar Vladimir Monomakh, used chaga to heal his lip tumors.
Chaga powder has a long history of traditional use for medicinal purposes, pipe smoking rituals, and mystical future forecasts. Finnish soldiers used chaga as a coffee substitute during World War II.
East Asian Traditions
In China and Korea, empirical evidence suggests that for centuries, chaga was traditionally taken as a tea to treat several ailments including pathogenic infections, gastrointestinal disorders, cancers, and liver disorders. Similarly in Japan, Greece, and parts of Eastern Europe, the mushroom has a history of use in folk medicine as a treatment for ulcers, gastritis, and tuberculosis. Chaga extracts have been used in Korea, China, Russia, Japan, and Siberia for their beneficial effects on lipid metabolism and cardiac function, as well as for antibacterial, anti-inflammatory, antioxidant, and antitumor activities.
Formal Pharmacological Recognition in Russia
In Russia, I. obliquus is considered a non-specific medicine for gastritis, gastric ulcer, and polyposis, and is used for precancerous therapy in liquid or tablet form, as a complex drug "Befungin," represented by a concentrated extract of chaga mushrooms. In 1955, chaga mushrooms were officially recognized as a medical treatment in Russia.
Cultural Note: Solzhenitsyn and Western Popularization
One of the most notable historical figures associated with chaga is the Russian author and Nobel laureate Aleksandr Solzhenitsyn, who mentioned the mushroom in his literary works and credited it with aiding his recovery from cancer. Solzhenitsyn's writings brought international attention to chaga and its potential health benefits, sparking further interest in this fungus.
3. Key Constituents and Active Compounds
Overview of Phytochemistry
As of 2022, more than 250 secondary metabolites have been identified in chaga including betulin, vanillic acid, terpenoids, and lanosterol. Chemical analysis of chaga mushroom demonstrated that it comprises polysaccharides, triterpenes, polyphenols, melanin, and steroids. Bioactive compounds isolated from chaga include polysaccharides, terpenoids, lignans as well as oxalic, gallic, protocatechuic, and p-hydroxybenzoic acids.
Beta-Glucans and Polysaccharides
The immunomodulating activity of this mushroom is based largely on its high content of β-glucans. Macro and micro nutrients identified from chaga extracts include carbohydrates (β-glucans, xylogalactoglucose), lipids (fecostrol, episterol, β-sitosterol), and polyphenols (inonoblins A, phelligridins D, ferulic acid, foscoperianol D, vanillic acid). Polysaccharides are considered among the most pharmacologically active fractions: polysaccharides from chaga mycelium work by triggering the immune system, while those from chaga sclerotium directly block protein synthesis in malignant cells.
Betulin and Betulinic Acid
These triterpenoid compounds originate from the birch bark that chaga colonizes — not from the fungus itself. As chaga grows, it absorbs and concentrates betulin from the birch tree and converts a portion into betulinic acid. This is why birch-grown chaga is considered essential: chaga cultivated on other substrates will not contain meaningful levels of these compounds.
Derivatives of betulin stimulate collagen synthesis in normal human fibroblasts. Betulin can be easily converted into betulinic acid, a compound that has anti-malarial, antifungal, anticancer, and anti-inflammatory activity. Betulin and betulinic acid are the most effective compounds used against skin inflammation. Betulin, betulinic acid, and their derivatives can be used against melanoma skin cancer, epidermoid carcinoma, and actinic dermatosis. Betulin and betulinic acid have shown promising potential as antimicrobial and anti-inflammatory agents. With anti-inflammatory activities, these compounds are reported to modulate the activities of immune cells and prevent pro-inflammatory production.
Triterpenoids: Inotodiol, Ergosterol Peroxide, and Trametenolic Acid
Triterpenoids such as inotodiol and ergosterol peroxide found in chaga mushrooms have exhibited anti-cancer properties by inducing apoptosis, inhibiting cell proliferation, and suppressing angiogenesis. Ergosterol peroxide has anticancer, antimicrobial, and immunosuppressive activity.
A lanostane-type triterpenoid named inotodiol was demonstrated to exhibit antitumor activities by inducing apoptosis in HeLa cells through the p53-dependent pathway. Enzymatic assay and inhibition kinetics analysis revealed that triterpenoids isolated from I. obliquus exert significant inhibitory activity against the α-glucosidase brush border enzyme, demonstrating their anti-diabetic properties.
Acetate and petroleum ether extracts significantly reduced nitric oxide (NO) generation and NF-κB luciferase activity in macrophage RAW 264.7 cells and induced cytotoxicity in vitro in human prostate cancer PC3 and breast cancer MDA-MB-231 cells. Inotodiol, ergosterol peroxide, and trametenolic acid were recovered from these two fractions. Both ergosterol peroxide and trametenolic acid were cytotoxic to the human prostatic carcinoma cell PC3 and the human breast cancer MDA-MB-231.
Melanin
The dark exterior of chaga is extremely rich in melanin, the same class of pigments found in human skin. Research suggests melanin may contribute to chaga's antioxidant activity and its traditional association with skin health, though human studies on this mechanism remain limited. Studies have demonstrated that polysaccharides, melanin, and polyphenols in chaga extract act as immunomodulating and anti-inflammatory agents.
Phenolic Acids and Lignin Derivatives
Oxalic, gallic, protocatechuic, and p-hydroxybenzoic acids have been identified in chaga extracts. Water-soluble lignin derivatives have also been identified as bioactive constituents with anticancer properties. Research has reported that the variety of phenolic compounds in chaga extract are the main ingredient responsible for its anti-inflammatory and antioxidant activities in vitro and in vivo.
4. Scientific Evidence by Area of Use
A critical overarching finding from the research literature is that there is very little human research available for chaga, and as such, definitive dosage recommendations cannot be made, as further research is required. Evidence supporting these benefits is limited to in vitro or animal studies, with only one case series published in humans. The following sections summarize available evidence by health area, with evidence strength characterized honestly.
4.1 Immunomodulation
Chaga demonstrated antitumor, antimutagenic, antiviral, antiplatelet, antidiabetic, immunomodulating, anti-inflammatory, and pain-relieving properties in vitro. Studies in murine models indicate that a chaga extract (0.1, 1.0, and 10.0 mg, administered orally once daily for 21 days; 20 μg or 200 μg, given intraperitoneally on days 0 and 21) inhibited allergen-induced systemic anaphylactic shock. Significant reductions were observed in immunoglobulin E production (P < .01), with intraperitoneal administration reported to be more effective than the oral route.
Evidence strength: Chaga mushroom tea and extracts have been marketed for their antioxidant and immunostimulatory effects, mainly supported by in vitro and in vivo studies. However, clinical trials are needed to confirm such effects. No robust, replicated, randomized controlled trials in humans have been published confirming immunomodulatory benefits.
4.2 Antioxidant Activity
Results from a small clinical study suggest chaga's potential to inhibit oxidative stress. An extract, at variable doses of 10 mg/mL to 500 mg/mL, was shown to decrease hydrogen peroxide–induced DNA damage in peripheral lymphocytes derived from healthy individuals (n = 20; P < .001) and those with inflammatory bowel disease (n = 20; P < .001). Larger randomized clinical trials are needed to determine the significance of these findings.
The presence of antioxidants, such as melanin, flavonoids, and phenolic compounds, in chaga may also contribute to their potential anti-cancer properties by protecting cells from oxidative stress and DNA damage. The constituents 3β-hydroxy-lanosta-8,24-dien-21-al and inotodiol produce antimutagenic and antioxidative activities.
Evidence strength: One small clinical study has been published (n = 40 total across two groups); all other evidence remains preclinical. The one human study was not a randomized controlled trial and requires larger-scale replication.
4.3 Anti-Inflammatory Activity
Studies have demonstrated that polysaccharides, melanin, and polyphenols in chaga extract act as immunomodulating and anti-inflammatory agents. These anti-inflammatory agents produce their effects by regulating pro-inflammatory cytokines and mediators.
Previous studies have demonstrated that alcoholic extracts from chaga possess significant anti-inflammatory effects in vivo and in vitro. Specifically, chaga extracts have been shown to suppress NF-κB signaling — a key pathway governing the expression of pro-inflammatory cytokines. Studies showed that chaga polysaccharide treatment significantly decreased alanine aminotransferase (ALT) level, aspartate aminotransferase (AST), malondialdehyde (MDA), and nitric oxide (NO), and increased the contents of antioxidant enzyme superoxide dismutase (SOD) and glutathione (GSH). The protection was partly due to anti-inflammatory effects through inhibiting the TLRs/NF-κB signaling axis and activating an antioxidant response by inducing the Nrf2/HO-1 signaling.
Evidence strength: Predominantly in vitro and animal-model data. No human clinical trials specifically investigating anti-inflammatory endpoints for chaga have been published.
4.4 Anticancer Properties
In vitro studies are the primary source of chaga's anticancer reputation. A chaga fraction prepared from dried fruiting bodies was subjected to anticancer evaluation in human lung carcinoma (A549), colon adenocarcinoma (HT-29), and rat glioma (C6) cell cultures. A range of assays including MTT, BrdU, LDH, wound assay, and ELISA were applied. Chaga fraction elicited anticancer effects attributed to decreased tumor cell proliferation, motility, and morphological changes. Of note is the fact that it produced no or low toxicity in tested normal cells.
Chaga extracts and its constituents showed inhibitory and pro-apoptotic effects against colon, lung, and liver cancer cells, and the active constituent inotodiol exhibited antitumor activity against cervical cancer cells. Chaga has also been shown to induce selective apoptosis in tumor cells without impacting healthy cells, and inhibited melanoma in a murine model.
Further research, including human clinical trials, is necessary to determine the efficacy and safety of these compounds for cancer treatment.
Evidence strength: Entirely preclinical (cell lines and animal models). No human clinical trials exist demonstrating anticancer efficacy of chaga in cancer patients. Preclinical data are promising but cannot be extrapolated to human clinical use.
4.5 Antidiabetic Activity
Chaga polysaccharides (at a dose of 50 mg/kg orally, once daily, for 4 weeks) decreased fasting plasma glucose levels, enhanced glycometabolism, and regulated inflammatory cytokines in streptozotocin-induced diabetic mice, via modulating oxidative stress and inflammatory factors.
Wang and Zhang investigated the anti-diabetic effects and the potential mechanism of chaga polysaccharides in vivo and found that polysaccharides ameliorated insulin resistance and lipid metabolism disorders in streptozotocin-induced type 2 diabetic mice. The proposed mechanism involves the PI3K-Akt signal pathway. Enzymatic assay and inhibition kinetics analysis also revealed that triterpenoids isolated from I. obliquus exert significant inhibitory activity against the α-glucosidase brush border enzyme, demonstrating anti-diabetic properties.
Other studies report the mushroom's general impact on the immune system and its potential in improving insulin resistance in type 2 diabetes.
Evidence strength: Exclusively animal and in vitro. No controlled clinical trials in humans with diabetes have been conducted or published. The antidiabetic effects observed in rodent models have not been validated in human studies.
4.6 Antiviral Activity
Numerous literature data indicate that extracts from I. obliquus show very good antiviral activity. Human influenza A and B and horse influenza A are also inhibited by constituents of the black exterior surface of chaga. Betulin, mycosterol, and lupeol, which are all found in mushrooms, are thought to be the primary antiviral agents.
An aqueous extract from chaga was studied for its ability to prevent herpes simplex virus entry through inhibition of viral-induced membrane fusion.
Evidence strength: In vitro only. No human antiviral trials have been conducted.
4.7 Hepatoprotective Effects
Studies on chaga polysaccharide (IOPS) hepatoprotective effects showed that treatment significantly decreased the liver coefficient, alanine aminotransferase (ALT), aspartate aminotransferase (AST), malondialdehyde (MDA), and nitric oxide (NO), and increased the contents of antioxidant enzyme superoxide dismutase (SOD) and glutathione (GSH). The protection was partly due to its anti-inflammatory effects through inhibiting the TLRs/NF-κB signaling axis and activating an antioxidant response by inducing the Nrf2/HO-1 signaling.
Evidence strength: Animal model data only. No human hepatoprotective clinical trials exist for chaga.
4.8 Anti-Fatigue Effects
Chaga polysaccharides (0, 100, 200, and 300 mg/kg/d orally for 14 days) alleviated fatigue in mice by enhancing swimming time and the glycogen content of liver and muscle, while decreasing blood lactic acid and serum urea nitrogen levels. Oral administration of polysaccharides from chaga increased exercise endurance and biological measures related to fatigue.
Evidence strength: Animal model data only. Results have not been replicated in human trials.
4.9 Skin Health
Research investigated the potential of chaga to reduce melanin pigmentation and its use as a skin whitening ingredient in cosmetics, focusing on tyrosinase, an enzyme that stimulates pigment production. It was discovered that the tyrosinase enzyme was inhibited by betulin and trametenolic acid, but other compounds such as inotodiol and lanosterol activated tyrosinase and increased pigment synthesis in laboratory cells. Pigment reduction may assist people with darker patches to achieve a more even skin tone, whilst pigment activation may be beneficial for those who have lost or decreased their pigment.
Evidence strength: In vitro only. No human dermatological clinical trials exist for topical or oral chaga administration for skin pigmentation or related outcomes.
5. Body Systems and Health Areas Associated with Chaga
Based on the available preclinical literature, chaga has been associated with effects on the following body systems:
- Immune system: The immunomodulating activity of this mushroom is based on its high content of β-glucans.
- Gastrointestinal system: In Russia, I. obliquus is considered a non-specific medicine for gastritis, gastric ulcer, and polyposis.
- Metabolic / endocrine system: Aqueous extracts of chaga, particularly polysaccharides, exhibited anti-inflammatory effects in animal models of colitis and enhanced lipid metabolism. Chaga-derived polysaccharides also exhibited protection against diabetes and hepatic diseases.
- Cardiovascular system: Chaga extracts have been used in Korea, China, Russia, Japan, and Siberia for their beneficial effects on lipid metabolism and cardiac function.
- Hepatic system: As described in the hepatoprotective section, animal data suggest modulation of liver enzymes and antioxidant pathways.
- Integumentary system (skin): Preclinical data suggest modulation of tyrosinase activity and melanin production through specific chaga compounds.
Modern research provides scientific evidence of the therapeutic properties of I. obliquus extracts, including anti-inflammatory, antioxidant, anticancer, anti-diabetic, anti-obesity, hepatoprotective, renoprotective, anti-fatigue, antibacterial, and antiviral activities. However, nearly all of this evidence is preclinical.
6. Dosage Forms and Doses Reported in Studies
Regulatory Guidance
According to Health Canada mushroom monograph references, total daily intake from all chaga sources should not exceed 3.6 grams of dried mushroom equivalent. This limit applies across formats, including tea, powder, tinctures, and extracts combined.
Human Research Dosages
In the sole identified small clinical study investigating antioxidant/DNA protection, a chaga extract at variable doses of 10 mg/mL to 500 mg/mL was applied ex vivo to peripheral lymphocytes from healthy individuals (n = 20) and those with inflammatory bowel disease (n = 20). This was an ex vivo study applying extract to cells, not an oral dosing trial in humans.
Preclinical (Animal Study) Dosages
In mouse studies, chaga polysaccharides at doses of 0, 100, 200, and 300 mg/kg/d orally for 14 days alleviated fatigue, and at a dose of 50 mg/kg orally, once daily, for 4 weeks decreased fasting plasma glucose levels in streptozotocin-induced diabetic mice.
In murine allergy models, a chaga extract at 0.1, 1.0, and 10.0 mg administered orally once daily for 21 days, or 20 μg or 200 μg given intraperitoneally on days 0 and 21, inhibited allergen-induced systemic anaphylactic shock, with significant reductions in IgE production.
Available Supplement Forms
Chaga is not commonly consumed in raw form due to its bitter nature. Instead tea made from the whole mushroom is more popular. Chaga extracts are also marketed as supplements in the form of capsules, tablets, and teas. Given the absence of robust human trials, there is very little human research available for chaga and dosage recommendations cannot be made, as further research is required.
Traditional Preparation Dosages
Traditional preparation methods use hot water extraction to release water-soluble constituents. Gentle simmering below boiling temperature is preferred, as aggressive boiling is not traditionally used.
7. Safety Considerations and Drug Interactions
Oxalate Nephropathy: Documented Case Reports
Due to its high oxalate content, excessive ingestion of chaga mushroom can result in acute oxalate nephropathy caused by the deposition of calcium oxalate crystals in the renal tubules. Multiple case reports have been published:
- Case 1: Oxalate nephropathy was reported in a 72-year-old woman with liver cancer after ingesting chaga mushroom powder (4–5 teaspoons daily for 6 months). Hemodialysis was required but renal function did not recover.
- Case 2: A 69-year-old man who ingested chaga mushroom powder (10–15 g per day) and vitamin C (500 mg per day) for 3 months developed acute kidney injury (AKI) with the clinical manifestations of nephrotic syndrome. Pathological findings showed focal acute tubular injury and the deposition of calcium oxalate crystals in the tubules. Light microscopy showed interstitial fibrosis and tubular atrophy, and electron microscopy showed the effacement of the foot processes in podocytes. The diagnosis was acute oxalate nephropathy accompanied by minimal change disease (MCD).
- Case 3: End-stage renal disease was reported in a 49-year-old man following long-term consumption of chaga mushroom for atopic dermatitis. Hemodialysis was required but renal function did not recover.
There are two case reports of kidney failure and one case report of acute oxalate nephropathy in patients taking chaga mushroom powder doses of 3–22 grams daily for six months to five years. Renal biopsies showed tubular atrophy, interstitial fibrosis, and the presence of oxalate crystals. In all of these cases, the kidney damage was attributed to the high oxalate content in chaga mushroom.
Interaction with Anticoagulant and Antiplatelet Drugs
Chaga extract inhibited platelet aggregation in a murine model. It may also have synergistic effects when used with anticoagulant/antiplatelet drugs. In vitro and animal research suggests that chaga mushroom extract might inhibit platelet aggregation. Chaga should therefore be used with caution in combination with drugs or supplements with antiplatelet or anticoagulant effects due to an increased risk of bleeding. Additionally, people with bleeding disorders should use caution when taking chaga mushroom. However, this risk is theoretical and has not been shown in human research.
Interaction with Hypoglycemic Agents
In vitro, chaga had additive effects in lowering blood sugar levels. The clinical significance of this finding is yet unknown. Animal research suggests that chaga mushroom might decrease blood glucose levels and increase insulin levels. Caution is warranted when chaga mushroom is used in combination with antidiabetes drugs and herbs or supplements with hypoglycemic potential due to the additive risk of hypoglycemia. However, this risk is theoretical and has not been shown in human research.
Overharvesting and Sustainability
Efforts are underway to develop cultivated substitutes of wild chaga due to overharvesting of natural reserves. Wild-harvested chaga grows slowly on living birch trees and can take years to mature, making indiscriminate harvesting a sustainability concern.
General Safety Status
Very limited human research makes the safety of chaga uncertain. The efficacy and safety of chaga mushroom have not been proven by large-scale clinical trials or scientific methods, which has often led to harmful side effects in cases of excessive dosing. Patients and care teams should be aware of the possible risk of nephropathy associated with the use of chaga mushroom and its interactions with antiplatelet or anticoagulant drugs as well as with hypoglycemic agents.
References
Volver